Shuanghuanglian Oral Solution Veterinary Grade API, designated SHL-VET-API-ORS, is a standardized multi-marker botanical active pharmaceutical ingredient prepared from the decoction of Lonicera japonica Thunb., Scutellaria baicalensis Georgi, and Forsythia suspensa (Thunb.) Vahl. The API is released as a hygroscopic brownish-yellow fine powder, and the extraction ratio is controlled relative to the native herb mixture to maintain reproducible marker content. It is intended for formulation into tablets, injections, capsules, powders, granules, premix, and oral solutions for veterinary species. Identity and potency are anchored to three HPLC-UV marker compounds: chlorogenic acid (CAS 327-97-9), baicalin (CAS 21967-41-9), and phillyrin (CAS 487-41-2). The product differs from unstandardized Shuanghuanglian herbal powders and from single-component synthetic anti-infective APIs by its tri-marker standardization, microbial and residual solvent controls aligned to veterinary routes of administration, and a particle-size profile suitable for dry blending, wet granulation, and sterile filtration after reconstitution.

What are the release specifications for SHL-VET-API-ORS?

Release is determined by a multi-marker HPLC-UV method using a C18 column (250 mm × 4.6 mm, 5 µm), mobile phase acetonitrile–0.1% phosphoric acid linear gradient, flow rate 1.0 mL/min, column temperature 30°C, injection volume 10 µL. Detection wavelengths are 327 nm for chlorogenic acid and 280 nm for baicalin and phillyrin. The acceptance criteria in Table 1 are applied as part of the certificate of analysis.

Thermal history is controlled because chlorogenic acid degrades under prolonged high-temperature dry heat. Aqueous decoction is performed at 95–100°C for 60–90 min in jacketed extraction vessels, followed by vacuum concentration at 60–70°C and spray drying with rotary atomizer inlet 160–175°C and outlet 75–85°C. When inlet temperature exceeds 180°C for more than 20 min during production campaigns, the chlorogenic acid HPLC peak area has been observed to decline below the lower release threshold in some batches, requiring dilution or recalculation of the label claim. The pH of the concentrated decoction is maintained between 5.0 and 6.5 to avoid hydrolysis of baicalin to baicalein; below 4.0, precipitation of flavonoid aglycones increases and solution clarity fails injectable-grade limits. These processing boundaries are not universal for all botanical extracts and must be validated for each extraction line because published data for this specific ternary extract configuration are limited.

When the API is diverted to injection-grade processing, what additional controls are introduced?

The dry API intended for injectable solutions is subjected to air-jet milling to D90 ≤25 µm, then reconstituted in Water for Injections at 40–50°C with gentle agitation. The solution is clarified through 0.45 µm and 0.22 µm polyethersulfone filters; terminal sterilization by moist heat at 121°C for 15 min is not recommended for this API because baicalin and chlorogenic acid show measurable loss under these conditions, and aseptic filtration is the preferred manufacturing route. The reconstituted solution is adjusted to pH 5.5–6.5 using sodium hydroxide or hydrochloric acid. Particulate matter is controlled by Ph. Eur. 2.9.19 or 2.9.20; the solution must meet injection-grade limits of ≤6000 particles ≥10 µm and ≤600 particles ≥25 µm per container, but finished product limits are assigned based on dose volume. Endotoxin control is applied at the API stage only for injection grade; the limit is derived from the maximum intended daily dose per kilogram of body weight for the target species. In multi-dose injectable formulations, antimicrobial preservative compatibility must be verified because phenolic constituents can bind to benzyl alcohol at concentrations above 1.0% v/v and reduce preservative efficacy.

Dry dosage-form compatibility and powder rheology

The oral powder, capsule, granule, tablet, and premix routes require different modifications of the base API. Direct-compression tablet formulations typically require pre-drying at 60°C for 2 h when ambient relative humidity exceeds 60%; otherwise moisture uptake above 5.0% produces sticking and capping on rotary tablet presses. A formulation containing microcrystalline cellulose type 102, crospovidone, and 0.5–1.0% colloidal silicon dioxide is used when the API angle of repose exceeds 42°. Tablet hardness is controlled at 60–100 N on a Schleuniger hardness tester, and friability is maintained at NMT 1.0% according to Ph. Eur. 2.9.7. For wet granulation, a binder solution of ethanol 60–70% v/v is preferred over aqueous binder because the dry extract becomes tacky at moisture levels above 8%. Capsule filling is performed with dry powder blends at 20–25°C and relative humidity ≤40% to maintain plug formation. Powder and premix operations use ribbon blenders operating at 0.4–0.6 m/s impeller tip speed for 15 min after geometric dilution with lactose monohydrate or maltodextrin carriers. Batch-to-batch variation in bulk density of the spray-dried API is observed between 0.38 g/cm³ and 0.52 g/cm³, which requires adjustment of fill volume and compression force during tablet and capsule manufacture.

For oral solution preparations, the API is reconstituted in purified water at 40–50°C, and the pH is adjusted to 5.5–6.5. Precipitation occurs if the solution is buffered below 4.0, and darkening is accelerated if the solution is stored above 30°C for more than 24 h without stabilizer. Solutions intended for drinking water medication are filtered through 10 µm inline filters to remove undissolved botanical particulates. Published data for this specific configuration is limited; therefore, the finished solution must be evaluated for clarity, filtration recovery, and marker concentration after 24 h under the intended farm storage conditions.

Residual solvent limits in the veterinary API differ from human-grade material

The veterinary stress is placed on VICH GL18 rather than ICH Q3C, although the two guidance documents share solvent categories. The API is specified as Class 1 solvent absent because benzene and carbon tetrachloride are not permitted in veterinary marker extracts. Methanol, if used as an extraction or crystallization solvent, is controlled as a Class 2 solvent with a limit of 3000 ppm; ethanol and ethyl acetate are controlled as Class 3 solvents with limits not exceeding 0.5% w/w each unless otherwise justified. Pesticide residue controls follow Ph. Eur. 2.8.13 or equivalent regional pharmacopoeial methods, and aflatoxin limits are aligned to target species feed exposure. Compared with human-grade Shuanghuanglian oral solution API, the veterinary grade permits broader microbial limits for oral and premix routes but imposes stricter endotoxin control when the same API is designated for injection grade. The veterinary product also differs from simple dry herbal powders: the extraction and spray-drying process reduces naturally occurring bacteria, molds, and plant cell fragments, while the tri-marker HPLC-UV release specification prevents substitution or harvest-season drift from altering the final dosage form.

A premix integration scenario illustrates the practical boundary conditions. The API is first adsorbed onto a maltodextrin or silicon dioxide carrier at 0.5–2.0 wt% loading in a low-shear ribbon blender, then diluted into the finished feed intermediate at the authorized veterinary formulation rate. Blend uniformity is assessed by sampling 10 locations according to the approved protocol; the relative standard deviation of chlorogenic acid content across samples should not exceed 5.0%. If the blend is held longer than 72 h at relative humidity above 60%, the API particles agglomerate and the D90 shifts above 150 µm, causing marker segregation in the final feed. In such circumstances, the batch is rejected or reprocessed through a 0.5 mm screen before release. For granule manufacture, wet granulation with 60–70% v/v ethanol followed by fluid-bed drying at 45–50°C maintains the three marker compounds within 90.0–110.0% of label claim; drying at 70°C or above for more than 30 min can selectively reduce chlorogenic acid content and shift the HPLC-UV fingerprint outside specification.